DrugTimes Innovative siRNA Portfolio: De-Risked, Multi-Tissue Targeted, and Ready for Global Partnership
The global landscape of chronic disease therapeutics is undergoing a profound transformation, with siRNA (small interfering RNA) emerging as a cornerstone of next-generation precision medicine. Unlike conventional small molecules or biologics that act at the protein level, siRNA silences disease-driving genes at the mRNA stage, delivering sustained efficacy, high specificity, and a favorable safety profile—addressing long-standing unmet needs in obesity, diabetes, cardiovascular disease (CVD), metabolic dysfunction-associated steatohepatitis (MASH), hepatitis B virus (HBV), and beyond.
Within DrugTimes network, we have built a premium portfolio of clinically validated siRNA assets designed to tackle these high-burden, billion-dollar markets. We possess a comprehensive multi-tissue delivery system: our mature GalNAc (N-acetylgalactosamine) conjugation platform achieves precise liver targeting via the ASGPR receptor, enabling potent, durable gene silencing with minimal off-target effects for liver-centric indications including MASH and HBV. Beyond liver-targeted technologies, we have also developed a full suite of extrahepatic delivery platforms capable of efficient siRNA delivery to diverse organs and tissues such as adipose tissue, cardiovascular tissues, muscle and systemic circulation, breaking the tissue limitation of traditional GalNAc technology and supporting the development of siRNA drugs for extrahepatic diseases. Each asset in our pipeline is de-risked through rigorous preclinical testing, with robust proof-of-concept (PoC) in relevant animal models and clear pathways to IND-enabling studies.
1. Obesity & Metabolic Disorders (Obesity, Type 2 Diabetes, MASH)
- INHBE siRNA: Suppresses liver-derived Activin E, promoting fat breakdown, reducing visceral adiposity, and improving insulin sensitivity—with preclinical data showing significant weight loss, preserved muscle mass, and no GI side effects.
- ALK7 siRNA: Leveraging our adipose-targeted delivery technology, this candidate acts directly on ALK7 receptors in adipose tissue, driving white fat browning, reducing hepatic steatosis, and addressing MASH’s underlying metabolic dysfunction.
- MASH-specific siRNAs: Target hepatic inflammatory and fibrogenic genes (e.g., TGF-β, COL1A1) via GalNAc liver delivery, reversing steatohepatitis and fibrosis in preclinical models—filling the critical gap for MASH, a disease with no approved therapies.
2. Cardiovascular Diseases (CVD)
CVD remains the leading cause of death globally, with dyslipidemia and hypertension as major risk factors. Our CVD portfolio adopts tissue-specific delivery strategies tailored to cardiovascular tissues:
- PCSK9 siRNA: A follow-on to inclisiran (Leqvio), with enhanced potency and durability, lowering LDL-C by >50% with twice-yearly dosing—ideal for hypercholesterolemia and atherosclerotic CVD.
- AGT siRNA: Targets liver angiotensinogen, the precursor of all angiotensins, enabling complete RAS pathway blockade to overcome “RAS escape” in hypertension—preclinical data shows sustained blood pressure reduction with a single dose.
- Lipid metabolism siRNAs: Target APOB, ANGPTL3, and other key genes, addressing hypertriglyceridemia and mixed dyslipidemia—with potential for once-every-3–6 months dosing. Our optimized systemic delivery platforms ensure stable distribution within cardiovascular tissues for consistent therapeutic effects.
3. Chronic Hepatitis B (HBV)
Over 250 million people worldwide live with chronic HBV, with current therapies (nucleos(t)ide analogs) requiring lifelong treatment and achieving functional cure rates of only ~1%. Our HBV siRNA candidates target HBV pgRNA and surface antigen (HBsAg), the root causes of persistent infection:
- Dual-target HBV siRNA: Simultaneously silences HBV DNA replication and HBsAg expression, with preclinical data showing potent HBsAg reduction and immune restoration—synergistic with TLR agonists for functional cure.
- Liver-specific delivery: GalNAc conjugation ensures selective hepatocyte uptake, minimizing systemic exposure and enhancing safety.
Why Partner with DrugTimes?
- Diversified Delivery Technologies: We combine industry-leading GalNAc liver targeting and proprietary extrahepatic delivery platforms, covering liver, adipose tissue, cardiovascular tissues and more, supporting R&D for both hepatic and systemic diseases.
- De-Risked Pipeline: All assets have strong preclinical PoC, with efficacy and safety validated in disease-relevant models (e.g., DIO mice for obesity, diet-induced MASH models, HBV transgenic mice).
- Best-in-Class Technology: Proprietary chemical modification technologies paired with multi-tissue delivery systems maximize siRNA stability, potency and tissue specificity.
- High-Growth Markets: Our assets address **$100B+ combined markets** (obesity: $50B+, CVD: $30B+, MASH: $20B+, HBV: $10B+), with significant first-mover potential.
- Flexible Partnership Models: We offer global licensing, co-development, and equity-based partnerships—tailored to your strategic goals, with transparent terms and full technical support.
Ready to Accelerate Your siRNA Strategy?
If you are seeking differentiated, de-risked siRNA assets to expand your pipeline in obesity, diabetes, CVD, MASH, HBV, or other high-impact diseases, DrugTimes is your ideal partner. Our portfolio combines cutting-edge RNAi technology, versatile multi-organ delivery systems, deep disease biology expertise, and a proven track record of translational success.
Contact us today to explore partnership opportunities, access detailed asset dossiers, and advance the next generation of siRNA therapeutics to patients worldwide.
DrugTimes | Innovate RNAi, Transform Health
Please contact DrugTimes BD Team at BD@drugtimes.cn, please include siRNA in the subject. Many thanks!
DISCLAIMER All content herein is for informational purposes only. It shall not be used for research and development, investment, medical treatment, business collaboration or any other commercial and personal activities. Please read with caution. Thank you for your understanding and support.
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 
